FiercePharma

Pfizer unleashes its stake in GSK's ViiV Healthcare for $1.9B

Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSK’s ViiV Healthcare. The New York powerhouse has agreed to ...
Seeking Alpha

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial

ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its long-acting HIV PrEP therapy cabotegravir was found to be more acceptable to ...
Seeking Alpha

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ...
Morningstar

ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges ...

Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those ...